Valuation: PolyPeptide Group AG

Market Cap 1.45B 1.61B 1.33B 1.21B 2.29B 151B 2.36B 15.98B 6.37B 81.1B 6.06B 5.93B 256B P/E 2026 *
54x
P/E 2027 * 28.7x
Enterprise Value 1.55B 1.73B 1.43B 1.3B 2.45B 162B 2.52B 17.09B 6.81B 86.75B 6.48B 6.34B 274B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 2.74x
Free-Float
98.54%
Yield 2026 *
-
Yield 2027 * 0.15%
1 day-0.06%
1 week-5.16%
Current month-3.81%
1 month-8.08%
3 months-8.08%
6 months+3.59%
Current year+54.79%
1 week 40.05
Extreme 40.05
42.55
1 month 40.05
Extreme 40.05
44.3
Current year 23.1
Extreme 23.1
50.1
1 year 21.8
Extreme 21.8
50.1
3 years 13.22
Extreme 13.22
50.1
5 years 13.22
Extreme 13.22
146
10 years 13.22
Extreme 13.22
147.4
Manager TitleAgeSince
Chief Executive Officer 54 12/04/2023
Director of Finance/CFO 54 02/01/2024
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 73 01/01/2006
Chairman 69 01/04/2021
Director/Board Member 62 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
11/13/23 A Buy 2,500 0.0075%
10/12/23 A Buy 159,959 0.4829%
4/6/23 A Buy 45,842 0.1384%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%-5.16%+71.55%+96.31% 1.62B
+0.62%+0.77%+46.92%+137.61% 1,258B
-0.21%+5.82%+49.49%+91.27% 679B
+0.18%+2.61%+34.18%+111.75% 518B
+0.17%+2.76%+44.07%+69.71% 390B
-1.50%+1.30%+68.93%+44.54% 367B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 293B
-0.37%+0.28%+42.91%+73.04% 252B
+0.25%+1.07%+43.27%+122.96% 210B
Average -0.09%+0.70%+43.87%+84.51% 428B
Weighted average by Cap. +0.05%+1.17%+43.09%+96.00%

Financials

2026 *2027 *
Net sales 502M 560M 463M 420M 795M 52.47B 817M 5.54B 2.21B 28.11B 2.1B 2.06B 88.88B 576M 642M 531M 482M 912M 60.22B 938M 6.36B 2.53B 32.27B 2.41B 2.36B 102B
Net income 23.5M 26.21M 21.66M 19.67M 37.23M 2.46B 38.27M 259M 103M 1.32B 98.36M 96.28M 4.16B 45.23M 50.43M 41.68M 37.85M 71.64M 4.73B 73.64M 499M 199M 2.53B 189M 185M 8.01B
Net Debt 101M 113M 93.04M 84.5M 160M 10.55B 164M 1.11B 444M 5.65B 422M 414M 17.88B 131M 146M 121M 110M 207M 13.69B 213M 1.44B 575M 7.33B 548M 536M 23.18B
Projected Income Statement - Annual - PolyPeptide Group AG
Logo PolyPeptide Group AG
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Employees
1,460
Date Price Change Volume
10/11/26 CHF 40.40 +0.12% 8,948
09/11/26 CHF 40.35 +0.75% 6,355
06/11/26 CHF 40.05 -1.11% 21,455
05/11/26 CHF 40.50 -2.06% 17,693
04/11/26 CHF 41.35 -2.93% 24,358
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - PolyPeptide Group AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
43.85EUR
Average target price
46.32EUR
Spread / Average Target
+5.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyPeptide Group AG
  1. Stock Market
  2. Stocks
  3. PPGN Stock